Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology/Urology
Disease Category: Prostate Disorders
Trial Information
Enlarged Prostate Study
Phase 3 Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double-blind Clinical Evaluation of NX-1207 for the Treatment of BPH
Patient Inclusion Criteria:
- Males 45 and older
- History of BPH for at least 1 year
- Willing to stop BPH medications prior to treatment
Patient Exclusion Criteria:
- Prostatitis or chronic or intermittent pain in penis, testes, anal, or pelvic area within 12 months
- Clinical trial within 90 days
- Taking certain medications, including immunosuppressants, chemotherapy, male hormonal replacement, etc.
- Significant drug allergy
- Urinary tract infection more than once in 12 months
- Previous surgical treatment of the prostate
- History of self-catheterization or urinary retention
- Prostate or bladder cancer or pelvic irradiation
- PSA greater than or equal to 10
- Hemophilia
- Diabetes
- Neurological disease
- Spinal cord injury
- Stroke within 6 months
- Substance abuse
Michele Pleasant, Patient Recruitment Specialist
West Coast Clinical Research
5525 Etiwanda Ave., Suite 202
Tarzana, CA 91356
Phone: 818-776-0820, Ext. 101
Fax: 818-776-1269
EMail: mpleasant@wccresearch.com
View Google Map
Research Center Information: West Coast Clinical Research
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
